Cholinesterase inhibition: is there evidence for disease-modifying effects?

References

• Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1154-66
   PubMed Web of Science ®Google Scholar
• Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14(1):e1-26
   PubMed Web of Science ®Google Scholar
• Gauthier S. Long-term efficacy of cholinesterase inhibitors. Brain Aging 2002;2:9-22
   Google Scholar
• Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002;127(Suppl):6-19
   PubMedGoogle Scholar
• Farlow M, Anand R, Messina J Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44(4):236-41
   PubMed Web of Science ®Google Scholar
• Farlow M, Potkin S, Koumaras B, et al. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003;60(6):843-8
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54(12):2261-8
   Google Scholar
• Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352(23):2379-88
   PubMed Web of Science ®Google Scholar
• Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024-35
   PubMed Web of Science ®Google Scholar
• Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6(6):501-12
   PubMed Web of Science ®Google Scholar
• Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?. J Neurol Neurosurg Psychiatry 2005;76(10):1348-54
   PubMed Web of Science ®Google Scholar
• Ferris S, Lane R, Sfikas N, et al. Treatment response to rivastigmine in mild cognitive impairment: an enhanced statistical modeling approach Gender Med 2009;6:345-55
   Google Scholar
• Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20(2 Suppl. 1):S12-18
   PubMed Web of Science ®Google Scholar
• Mesulam MM. Some cholinergic themes related to Alzheimer's disease: synaptology of the nucleus basalis, location of m2 receptors, interactions with amyloid metabolism, and perturbations of cortical plasticity. J Physiol Paris 1998;92(3-4):293-8
   PubMed Web of Science ®Google Scholar
• Mesulam MM. The cholinergic innervation of the human cerebral cortex. Prog Brain Res 2004;145:67-78
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36(5):722-7
   PubMed Web of Science ®Google Scholar
• Holmes C, Ballard C, Lehmann D, et al. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005;76(5):640-3
   PubMed Web of Science ®Google Scholar
• Darvesh S, Hopkins DA. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 2003;463(1):25-43
   PubMed Web of Science ®Google Scholar
• Giacobini E. Butyrylcholinesterase: its role in brain function. In: Giacobini E (ed.) Butyrylcholinesterase: Its Function and Inhibitors. London: Martin Dunitz, 2003:1-20
   Google Scholar
• Bartzokis G. Acetylcholinesterase inhibitors may improve myelin integrity. Biol Psychiatry 2007;62(4):294-301
   PubMed Web of Science ®Google Scholar
• Legrand C, Ghandour MS, Clos J. Histochemical and biochemical studies of butyrylcholinesterase activity in adult and developing cerebellum. Effects of abnormal thyroid state and undernutrition. Neuropathol Appl Neurobiol 1983;9(6):433-53
   PubMed Web of Science ®Google Scholar
• Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 2004;25(1):5-18; author reply 49-62
   PubMed Web of Science ®Google Scholar
• Lane R, He Y. Roles of butyrylcholinesterase, acetylcholine and gender in neurodegeneration. in preparation
   Google Scholar
• Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999;12(4):307-23
   Web of Science ®Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2(8000):1403
   PubMed Web of Science ®Google Scholar
• Nizri E, Hamra-Amitay Y, Sicsic C, et al. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 2006;50(5):540-7
   PubMed Web of Science ®Google Scholar
• Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005;102(47):17213-8
   PubMed Web of Science ®Google Scholar
• Lane R, Farlow M. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res 2005;46:949-68
   PubMed Web of Science ®Google Scholar
• Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006;9(1):101-24
   PubMed Web of Science ®Google Scholar
• Ferris S, Feldman H, Nordberg A, et al. Progression from Mild Cognitive Impairment to Alzheimer's disease: effects of gender, butyrylcholinesterase genotype and rivastigmine treatment. Pharmacogenet Genom 2009;19:635-46
   Google Scholar
• Cedazo-Minguez A, Cowburn RF. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mol Med 2001;5(3):254-66
   PubMed Web of Science ®Google Scholar
• Lane R, He Y. Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE ε4, and hyperhomocysteinemia in neurodegenerative dementias. Medical Hypotheses 2009;73:230-50
   PubMed Web of Science ®Google Scholar
• Venneri A, McGeown WJ, Shanks MF. Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport 2005;16(2):107-10
   PubMed Web of Science ®Google Scholar
• Venneri A, Lane R. Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease. Neuroreport 2009;20:285-8
   PubMed Web of Science ®Google Scholar
• Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993;34(3):373-84
   PubMed Web of Science ®Google Scholar
• Nordberg A, Darreh-Shori T, Peskind E, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Current Alzheimer Research 2009;6:3-13
   Google Scholar
• Stefanova E, Blennow K, Almkvist O, et al. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 2003;338(2):159-63
   PubMed Web of Science ®Google Scholar
• McGeown W, Shanks M, Forbes-McKay K, et al. Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease. Current Alzheimer Research 2009;in press
   Google Scholar
• DeCarli C. The role of neuroimaging in dementia. Clin Geriatr Med 2001;17(2):255-79
   PubMed Web of Science ®Google Scholar
• Venneri A. Imaging treatment effects in Alzheimer's disease. Magn Reson Imaging 2007;25(6):953-68
   PubMed Web of Science ®Google Scholar
• Kadir A, Darreh-Shori T, Almkvist O, et al. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl) 2007;191(4):1005-14
   PubMed Web of Science ®Google Scholar
• Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21(8):1317-27
   PubMed Web of Science ®Google Scholar
• Blesa R, Bullock R, He Y, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genom 2006;16(11):771-4
   PubMed Web of Science ®Google Scholar
• Bullock R, Bergman H, Touchon J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 2006;22(3):483-94
   PubMed Web of Science ®Google Scholar
• Touchon J, Bergman H, Bullock R, et al. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Curr Med Res Opin 2006;22(1):49-59
   PubMed Web of Science ®Google Scholar